BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol 2021;75 Suppl 1:S67-81. [PMID: 34039493 DOI: 10.1016/j.jhep.2020.11.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen J, Li X, Zeng P, Zhang X, Bi K, Lin C, Jiang J, Diao H. Lamina propria interleukin 17 A aggravates natural killer T-cell activation in autoimmune hepatitis. FASEB J 2022;36:e22346. [PMID: 35583908 DOI: 10.1096/fj.202101734RRR] [Reference Citation Analysis]
2 Park J, Kim J, Kim S, Jung JH, Jang M, Park S, Lee M, Kim H, Suk KT, Kim DJ. Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics. Biomedicines 2022;10:1288. [DOI: 10.3390/biomedicines10061288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sharma A, Roy A, Premkumar M, Verma N, Duseja A, Taneja S, Grover S, Chopra M, Dhiman RK. Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial. Hepatol Int. [DOI: 10.1007/s12072-022-10312-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 de Vos WM, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: mechanistic insights. Gut 2022;71:1020-32. [PMID: 35105664 DOI: 10.1136/gutjnl-2021-326789] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 28.0] [Reference Citation Analysis]
5 Kalo E, Read S, Ahlenstiel G. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. Livers 2021;1:147-79. [DOI: 10.3390/livers1030014] [Reference Citation Analysis]
6 Louissaint J, Deutsch-link S, Tapper EB. Changing Epidemiology of Cirrhosis and Hepatic Encephalopathy. Clinical Gastroenterology and Hepatology 2022;20:S1-8. [DOI: 10.1016/j.cgh.2022.04.036] [Reference Citation Analysis]
7 Li B, He Q, Rui Y, Chen Y, Jalan R, Chen J. Rapid detection for infected ascites in cirrhosis using metagenome next-generation sequencing: A case series. Liver Int 2021. [PMID: 34687275 DOI: 10.1111/liv.15083] [Reference Citation Analysis]
8 Lamatsch S, Sittner R, Tacke F, Engelmann C. Novel drug discovery strategies for the treatment of decompensated cirrhosis. Expert Opin Drug Discov 2021;:1-10. [PMID: 34971342 DOI: 10.1080/17460441.2022.2020755] [Reference Citation Analysis]
9 Xia Y, Shi H, Qian C, Han H, Lu K, Tao R, Gu R, Zhao Y, Wei Z, Lu Y. Modulation of Gut Microbiota by Magnesium Isoglycyrrhizinate Mediates Enhancement of Intestinal Barrier Function and Amelioration of Methotrexate-Induced Liver Injury. Front Immunol 2022;13:874878. [DOI: 10.3389/fimmu.2022.874878] [Reference Citation Analysis]
10 Xu J, Zhan Q, Fan Y, Lo EKK, Zhang F, Yu Y, El-Nezami H, Zeng Z. Clinical Aspects of Gut Microbiota in Hepatocellular Carcinoma Management. Pathogens 2021;10:782. [PMID: 34206200 DOI: 10.3390/pathogens10070782] [Reference Citation Analysis]
11 Fujimoto Y, Kaji K, Nishimura N, Enomoto M, Murata K, Takeda S, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H. Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity. World J Gastroenterol 2021; 27(48): 8323-8342 [DOI: 10.3748/wjg.v27.i48.8323] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Schulz MS, Gu W, Schnitzbauer AA, Trebicka J. Liver Transplantation as a Cornerstone Treatment for Acute-On-Chronic Liver Failure. Transpl Int 2022;35:10108. [DOI: 10.3389/ti.2022.10108] [Reference Citation Analysis]
13 Mitten EK, Baffy G. Microbiota transplantation in portal hypertension: promises and pitfalls. Clin Sci (Lond) 2022;136:425-9. [PMID: 35333331 DOI: 10.1042/CS20220029] [Reference Citation Analysis]
14 Bajaj JS, Shamsaddini A, Acharya C, Fagan A, Sikaroodi M, Gavis E, McGeorge S, Khoruts A, Fuchs M, Sterling RK, Lee H, Gillevet PM. Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosis. Gut Microbes 2021;13:1993584. [PMID: 34743650 DOI: 10.1080/19490976.2021.1993584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Åberg F, Helenius-hietala J. Oral Health and Liver Disease: Bidirectional Associations—A Narrative Review. Dentistry Journal 2022;10:16. [DOI: 10.3390/dj10020016] [Reference Citation Analysis]
16 Jalan R, Szabo G. New concepts and perspectives in decompensated cirrhosis. J Hepatol 2021;75 Suppl 1:S1-2. [PMID: 34039481 DOI: 10.1016/j.jhep.2020.12.008] [Reference Citation Analysis]
17 Liu J, Yang D, Wang X, Asare PT, Zhang Q, Na L, Shao L. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. Front Cell Infect Microbiol 2022;12:774335. [DOI: 10.3389/fcimb.2022.774335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Zhang S, Ji B, Zhong X, Zhong L, Yang L, Yang C. A Dynamic Nomogram Predicting Portal Vein Thrombosis in Cirrhotic Patients During Primary Prophylaxis for Variceal Hemorrhage. Front Med 2022;9:887995. [DOI: 10.3389/fmed.2022.887995] [Reference Citation Analysis]